Ambry Genetics and RainDance Technologies Announce Partnership for Diagnostics and Genomics Services
News Mar 17, 2010
A global leader for genetic testing and next generation sequencing services, Ambry Genetics is a CLIA certified and CAP accredited Diagnostic and Genomic Services company providing solutions to both clinical and research clients.
“Ambry Genetics has dedicated its investments in technology for the benefit of the scientific and research community,” said Ardy Arianpour, Director of Business Development. “We are motivated to provide our Diagnostic, Genomic and Research customers with the best solutions for their projects, and the addition of RainDance’s RDT 1000 adds a sequence-enrichment offering while providing an option for customers that are in need of high-throughput targeted sequencing with a high level of coverage, completeness and speed.”
Researchers can utilize the RDT 1000 and Ambry Genetics Next Generation Services to either greatly reduce study time, or to improve study quality by running more samples in the same time within the same experimental budget.
“We’re pleased to partner with Ambry Genetics to provide our microdroplet PCR-based solution in conjunction with Ambry’s genetic testing and next generation sequencing services ” said Chris McNary, Chief Commercial Officer of, RainDance Technologies. “PCR is the gold standard for sequence enrichment and allows for high-resolution analysis of rare genetic variations, a focus area of Ambry Genetics’ customers”. Ambry is currently offering RainDance’s sequence enrichment solution and may add two new applications, Methyl-Seq and Ultra-Deep Resequencing in the second half of 2010, further enhancing their customers’ ability to understand the origins and pathways of complex diseases."
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.